mix guidanc unexpect pharma declin medic
double-digit appear achiev room upsid particular
medic guid ambit first view factor one-tim nois
headwind pharma renew cvs/kr gener natur
sidelin believ worst like past
provid pharma segment guidanc mid-singl digit percentag revenu
growth high-singl low-doubl digit percentag oper profit declin management
attribut expect declin oper profit larg renew kr
two largest custom gener program expect headwind
lesser degre increment opioid-rel
litig expens contribut expect declin expect
declin pharma segment oper profit guidanc contrast
pharma oper profit guidanc mid-singl digit growth also renew contract
think differ may due mix busi
mail-ord contract like skew toward specialti grow
higher rate tradit brand drug addit renew in-line fiscal
year benefit one quarter without impact renew
surfac medic segment oper profit guidanc low-doubl
digit percentag growth look ambit think achiev must note
medic profit would in-line guidanc rang low- mid-singl
digit percentag declin incur charg relat exclus distribut
agreement cordi supplier impli oper profit would come
approxim guidanc impli result
also impact tsa exit occur addit benefit
increment cost save although benefit expect
off-set invest
base prepar remark call convers management believ
open settlement will accept settlement
unreason disproportion believ liabil view base
management comment call even though wholesal distributor drive
demand prescript opioid target lawsuit mani novel
unpreced legal claim go well beyond balanc credibl believ
distributor strong legal defens see note takeaway opioid litig
confer call management note us base simpli fact issu might
even abl get past summari judgement howev recognit
opioid crisi view simpli believ along
distributor would open reason settlement one encompass
mean state municipalities/c fairli proport real role
suppli chain suggest distributor offer initi bid
settlement may correct sinc unlik distributor
would look settl case consolid
pleas see page report import disclosur
would remain sidelin management continu execut turnaround
strategi cordi despit solid perform pharma segment turnaround
medic said progress in-lin expect servic level fill rate
cordi back order inventori expens trend management
remain confid cordi path profit growth end
better expect result pharma particularli top-lin beat larg due
specialti indic us macro environ may improv
progress turnaround medic
updat management strateg initi
growth
gross margin almost
ebit margin
share repo
top-lin growth high-singl digit
due better expect growth
specialti medic
gross margin closer greater
expect benefit red oak
sg come better oper
leverag cost reduct
share repo greater
top-lin growth low-singl
digit due weaker expect
gross margin due weaker
expect gener profit
 restructur cost weigh
share repo less
one three largest pharmaceut distribut compani
 oper billion pharmaceut market compani distribut
comprehens offer brand-nam gener pharmaceut over-the-count
healthcar product home healthcar suppli equip wide varieti
healthcar provid locat throughout includ acut care hospit health
system independ chain retail pharmaci mail-ord facil physician clinic
alternate-sit facil cardin oper today two report segment
pharmaceut medic cardin recent focus home health space
lower adj ep estim
respect also lower price target base revis
dcf analysi indic share trade adj ep estim
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per fiscal year end june cowen
million except per-shar data
compani report cowen compani
good gross gross chang sell gener oper interest pre-tax incom tax incom continu net incom deal-rel discontinu operations- non-recurring net incom dilut weight averag ep continu ep deal-rel ep non-recurring ex-disc ep chang year-over-year oper incom continu continu year end june cowen
million except per-shar data
compani report cowen compani
good gross gross chang sell gener oper interest pre-tax pre-tax incom tax net earn attribut non-controlling net incom continu net incom deal-rel discontinu operations- non-recurring net incom dilut weight averag adj chang year-over-year oper incom continu continu cowen
million
compani report cowen compani
asset trade receiv merchandis prepaid expens asset held sale discontinu ops- current pp goodwil total current liabil current portion long-term account accru liabil busi held sale disc ops- current long-term defer tax redeem non-controlling stockhold equiti common retain common share cumul foreign currenc non-controlling total stockhold total liabil stockhold short-term liquid ratio current sale day purchas account inventori ratio inventori capit structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti year end june cowen
million
compani report cowen compani
income/ loss cumul effect chang accounting- earn /loss discontinu operations- earn cont op b/f effect chg flow oper activ depreci sale provis loss account charg reorg busi charges- sale invest businesses- employe stock defer incom invest impair chang oper asset liabil account merchandis prepaid expens assets- account oper net cash use /provid op activ disc ops- net cash oper acquisit properti acquisit issuanc common purchas treasuri dividend common proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari capit owner financ non-recur year end june cowen
million
compani report cowen compani
flow oper activitiesnet cumul effect chang accounting- earn /loss discontinu earn cont op cumul effect chang adjust reconcil net earn net cash depreci sale asset loss debt sale carefus common stock- purchas in-process d- equiti provis defer incom tax provis bad debt chang fair valu conting consider oblig chang oper asset liabil net increas trade receiv increas increas net invest sales-typ leases- increas account oper item net net cash use /provid oper activ discontinu ops- net cash provid oper flow invest activ acquisition/divestitur subsidiari net cash acquir proce sale properti equip addit properti equip sale/ purchas market secur avail sale proce matur available-for-sal proce divestitur dispos held sale proce sale carefus common stock- net cash use /provid invest activ discontinu ops- net cash use invest flow financ activ payment conting net chang commerci paper short-term debt reduct long-term oblig net purchas non-controlling interests- proce interest rate swap terminations- proce long-term oblig net issuanc cost proce securit borrow payment premium debt extinguishment- proce issuanc common share tax benefit exercis stock purchas treasuri share net cash use /provid financ activ discontinu ops- net cash provid by/ use financ effect exchang rate chang cash equivalents- reclassfii asset held sale- net increas decreas chang fiscal year equival begin equival end fiscal year end june cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ
abil turn around medic segment integr risk relat cordi patient
recoveri manag abil deploy capit effect faster-than-
expect turnaround cordi
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
